Aurobindo Pharma
AUROPHARMA
Aurobindo Pharma Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 3,34,916 |
| Weekly | 2.94% | 38,04,380 |
| Monthly | 15.58% | 3,21,35,761 |
Aurobindo Pharma Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| AUROPHARMA | - | 2.94% | 15.58% |
| Index | - | - | - |
| Peer Avg. | -0.01% | 5.41% | 11.50% |
Aurobindo Pharma Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| AUROPHARMA | 20.87 | 1.94 | 6.14 | 10.16 | 10.67 | 2.07 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
Aurobindo Pharma Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | -17.00% | -51.78% | 10.16% | 10.67% |
| FY '20-21 | 12.80% | 77.18% | 24.65% | 26.68% |
| FY '19-20 | 13.57% | 21.87% | 17.00% | 17.40% |
Aurobindo Pharma Shareholding Pattern
Aurobindo Pharma Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 17,371.31 | 14,451.27 | 3,425.76 | 2,066.53 |
| FY '20-21 | 20,299.15 | 15,572.53 | 5,211.97 | 4,251.05 |
| FY '19-20 | 18,234.64 | 14,453.55 | 4,071.42 | 2,367.87 |
Aurobindo Pharma Peer Comparison
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| AUROPHARMA | 17,371.31 | 14,451.27 | 3,425.76 | 2,066.53 |
| GLAND | 4,400.71 | 2,890.31 | 1,734.33 | 1,211.91 |
| BIOCON | 4,961.10 | 4,183.65 | 1,215.60 | 532.30 |
Aurobindo Pharma Share Price
Aurobindo Pharma Limited is an Indian pharmaceutical company. The main activity of the company is the production and distribution of active pharmaceutical ingredients, branded drugs, generic drugs and related services. Its product portfolio is divided into seven therapeutic/product areas which include CNS (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Oral & Sterile, anti-infective, anti-diabetic and cephalosporins - orally. It develops various oncology and hormonal products. It develops topical and transdermal products for the therapeutic segment of dermatology. The company is also developing approximately three depot injections based on microsphere and nanosuspension technology platforms. The company distributes its products worldwide in about 150 countries. The company's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited and others.